You will select a chronic disease (I CHOSE COPD- Chronic Obstructive pulmonary disease) of interest to you and write a paper giving an overview of the pathophysiology of this disease, as well as its effect on other organ systems. You will also review one piece of patient education on this disease (this may be taken from an appropriate organization’ s website or other source) and evaluate it for cultural & literacy appropriateness. (please note that the paper will checked for originality using SafeAssign, our online plagiarism checker).
(Health Assessment class:)
The chronic disease paper will consist of the following sections:
– Introduction – Overview of the pathophysiology of your selected disease (COPD)
Chronic hepatitis with a large predominance of plasma cells: AUTOIMMUNE (LUPOID) HEPATITIS (chronic active hepatitis from any cause can look the same) Chronic hepatitis with lots of fatty change in a non-drinker (and nothing that says NASH):HEPATITIS CMallory's hyaline in zone 3, plus fat and polys: ALCOHOLIC HEPATITIS / NASH (also considerileal bypass or amiodarone toxicity) Random confluent-lytic necrosis: UNUSUAL VIRAL INFECTIONS, IN A BABY OR IMMUNOSUPPRESSED PERSON (* CMV, herpes simplexor zoster, adenovirus, echovirus; also consider whether the biopsy was obtained duringsurgery) Polys in the lumens of bile ducts: ASCENDING CHOLANGITIS * Mallory's hyaline in zone 1: Wilson's disease, primary biliary cirrhosis, amiodarone * Lipofuscin in Kupffer cells: A sign of recent (last few months) hepatocellular necrosis * d-PAS positive stuff in Kupffer cells: A marker that the patient is on hyperalimentation Polys in the portal areas, bile duct proliferation: Chronic or intermittent bile duct obstruction Bile lakes, bile duct proliferation, edema of the portal areas: Acute bile duct obstruction.
A famous and elaborate protocol by a naturopath for treatment of chronic hepatitis C, which centers around a very specialrecipe for breakfast museli, led to drops in transaminase levels but he made no effortto control for the fact that he also made his patients stop drinking alcohol.
Mahsa Jafari Giv, Alam Yoosuff, Ali Bazargan. . (2015) Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis. 148:2, e35-e37.
Kentaro Inoue, Ryoi Goto, Hideo Shimomura, Hiroshi Fukuda. . (2013) FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. 2, 113.
* Good news: In contrast to studies of selected patient populationswith various illnesses from decades ago, black and whitepeople with congestive heart failure seem to get equally good treatment (JAMA 289: 2517, 2003).
About 65% of patients have airflow limitation at presentation, and spirometry usually indicates restrictive ventilatory dysfunction, with reduced forced vital capacity (FVC) and reduced forced expiratory volume in 1 second (FEV1). At least 50% of patients also have concurrent obstructive airway disease, with a reduced ratio of FEV1 to FVC. Airway hyperreactivity occurs in 5 to 83% of patients. In 80% of patients presenting with abnormal spirometric findings, the values return to the normal range within 2 years.
Respiratory symptoms often include dyspnea, cough, vague chest discomfort, and wheezing. Chest radiographs in patients with sarcoidosis have been classified into four stages: stage 1, bilateral hilar lymphadenopathy without infiltration; stage 2, bilateral hilar lymphadenopathy with infiltration; stage 3, infiltration alone; and stage 4, fibrotic bands, bullae, hilar retraction, bronchiectasis, and diaphragmatic tenting. These so-called stages represent radiographic patterns and do not indicate disease chronicity or correlate with changes in pulmonary function.
P. Mencarini, R. Bellagamba, A. Oliva, P. Ghirga, M.L. Giancola, A. Corpolongo, T. Ascoli Bartoli, P. De Nardo, A. Baiocchini, F. Del Nonno, P. Narciso, E. Nicastri. . (2016) Pulmonary tuberculosis followed by sarcoidosis in an HIV-infected patient: A case report and a simplified diagnostic flowchart for diagnosis and treatment of sarcoidosis. 19, 150-154.
The Kveim–Siltzbach test has been used for many years in the diagnosis of sarcoidosis. The test is performed by injecting homogenate of human sarcoid tissue extract intradermally; 4 weeks later, the papule that develops at the site of injection is biopsied. This test is now used less often for several reasons. First, no commercially available preparation of the antigen exists. Second, the use of human tissue extracts for clinical purposes presents many constraints. Third, each new Kveim–Siltzbach preparation requires validation in vivo. Kveim–Siltzbach testing, if available, is most useful in patients whose lesions are not easily accessible by biopsy (i.e., lesions at sites other than the skin, lacrimal glands, peripheral lymph nodes, and conjunctivae) and who do not need immunosuppressive treatment during the 4-week waiting period between injection and biopsy. On the basis of our experience over the past 50 years at Mt. Sinai Medical Center, New York, where more than 10,000 Kveim–Siltzbach tests have been performed, the rate of true positive results appears to be over 50%, and the rate of false positive results is close to zero. A 3-to-4-mm scar from the punch biopsy necessitated by the test has been the only complication.
writer this assignment about questions and answers no need for introduction and conclusion just answer the questions please make sure you flow the guideline i have attached for you. you have to use this article as a start point ((Brill SE and Wedzicha JA. Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. International Journal of COPD. (2014) 9: 1241-1252.))) you can find it in google schooler also make sure you use google schooler for the rest of the references also make sure all the references are available and accessible.
Since sarcoidosis was last reviewed in the Journal 10 years ago, more than 5000 articles related to this condition have been published. This review summarizes recent advances and addresses pitfalls in the diagnosis and treatment of sarcoidosis.